Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05785741 · ClinicalTrials.gov registry record · Phase 1

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by DualityBio.

Recruiting
Registry status
Phase 1
Development phase
1,000
Enrollment target
20
Study locations

NCT05785741 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by DualityBio. The registered enrollment target is 1,000 participants, above the 188-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (432% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05785741, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by DualityBio.

RECRUITING
Registry status
Phase 1
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Trastuzumab
  • DRUG Osimertinib
  • DRUG DB-1310

Study Locations (20)

Florida

  • D&H Cancer Research Center LLC - Margate
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
  • BRCR global - Plantation
  • Florida Cancer Specialists - Sarasota
  • BRCR Medical Center Inc. - Tamarac

California

  • University of California, Davis Comprehensive Cancer Center - Sacramento
  • UCLA Hematology/Oncology - Santa Monica - Santa Monica

Jiangsu

  • Jiangsu Province hospital - Nanjing
  • Affiliated Hospital of Jiangnan University - Wuxi

Georgia

  • Research Site 111 - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Health System - Detroit

Ohio

  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center - Cincinnati

Tennessee

  • Tennessee Oncology, PLLC - Nashville

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-04-10
Est. Completion 2026-08-31
Phase Phase 1

Sponsor

DualityBio

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05785741

The ClinicalTrials.gov registry entry for NCT05785741 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 188-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (432% higher). The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT05785741 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Jiangsu.

Frequently Asked Questions

What is clinical trial NCT05785741 about?

NCT05785741 is a clinical study titled "A Study of DB-1310 in Advanced/Metastatic Solid Tumors". This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

What is the current status of trial NCT05785741?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,000 participants. The study started on 2023-04-10. Estimated completion is 2026-08-31.

What conditions does trial NCT05785741 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05785741?

The interventions under investigation include: Trastuzumab (DRUG), Osimertinib (DRUG), DB-1310 (DRUG).

Who is sponsoring clinical trial NCT05785741?

This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05785741 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.